Aclaris Therapeutics presented new Phase 2a results for its oral covalent inhibitor ATI‑2138 at the American Academy of Dermatology (AAD) Annual Meeting in Denver on March 20 2026. The company made an ePoster available electronically during the meeting, detailing the outcomes of an open‑label study in moderate‑to‑severe atopic dermatitis.
The ePoster confirmed a strong tolerability profile and clinically meaningful improvements. Patients receiving 10 mg BID achieved a mean 60.5 % reduction in the Eczema Area and Severity Index (EASI) at week 12, and the study also reported significant reductions in patient‑reported pruritus numeric rating scale (PP‑NRS) scores. Molecular analyses presented at the meeting showed down‑regulation of inflammatory mediators and fibrosis markers, supporting the drug’s mechanism of action.
These findings build on the July 29 2025 top‑line results and the September 2025 EADV Congress data, reinforcing ATI‑2138’s therapeutic potential in atopic dermatitis and supporting future studies in alopecia areata and other T‑cell‑mediated diseases.
Dr. Neal Walker, CEO, said: "These Phase 2a trial results represent a significant achievement for our ITK franchise by confirming the mechanism and corroborating our work on next‑generation ITK selective compounds. The objectives of this trial were to confirm the strong tolerability profile across multiple doses of ATI‑2138 over 12 weeks, to test the mechanism in AD before initiating our work in other diseases including alopecia areata, and to further validate ITK as an important therapeutic target; we accomplished each of these."
Aclaris remains a clinical‑stage biopharmaceutical company focused on immuno‑inflammatory diseases. The company reported a net loss of $64.9 million for 2025 on revenue of $7.8 million, with a cash balance of $151.4 million as of December 31 2025. In early March 2026, it raised $59.8 million through an ATM offering to fund ongoing clinical development.
The ePoster presentation is a key milestone that may influence investor perception of the company’s pipeline, but no significant market reaction or analyst commentary was identified at the time of the event.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.